AngeCool to enter full clinical trial:
This article was originally published in Clinica
Angeion has completed initial US trials in 20 patients of its AngeCool radiofrequency catheter ablation system for the treatment of supraventricular and atrial arrhythmias. The company will seek FDA permission to expand the trials of the product, which features a porous catheter tip to minimise blood coagulation. Other ablation technologies under development by Angeion include a linear RF ablation catheter for treating atrial fibrillation and two laser ablation products for the treatment of ventricular tachycardias.
You may also be interested in...
CBER is starting the year with four novel gene and cell therapy applications under review and rolling submissions underway for more.
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.